Literature DB >> 12388934

KCNQ1 gene mutations and the respective genotype-phenotype correlations in the long QT syndrome.

Ernest Herbert1, Maria Trusz-Gluza, Ewa Moric, Ewa Smiłowska-Dzielicka, Urszula Mazurek, Tadeusz Wilczok.   

Abstract

KCNQ1 (formerly called KVLQT1) is a Shaker-like voltage-gated potassium channel gene responsible for the LQT1 sub-type of LQTS. In general, heterozygous mutations in KCNQ1 cause Romano-Ward syndrome (LQT1 only), while homozygous mutations cause JLNS (LQT1 and deafness). To date, more than 100 families with mutations in this gene have been reported, most with their own novel 'private' mutations. The majority of these mutations are missense. However, other types of mutations, such as deletions, frame-shifts and splice-donor errors have also been reported. There is one frequently reported mutated region (the 'hot-spot'). KCNQ1 is now believed to be the most commonly mutated gene in LQTS. The combination of normal and mutant KCNQ1 alpha-subunits has been found to form abnormal IKS channels, hence mutations associated with the KCNQ1 gene are also believed to act mainly through a dominant-negative mechanism (the mutant form interferes with the function of the normal wild-type form through a 'poison pill' type mechanism) or loss of function mechanism. Even in the case of carriers of the same mutation, it is currently unknown why there are significant clinical phenotype variations in LQT1 patients. This question could be answered by increasing the number of patient genotypes studied. LQT1 patients experience a majority of their cardiac events (62%) during exercise, and only 3% occur during rest or sleep. Of the patients who experienced cardiac events while swimming, 99% were LQT1. Auditory stimuli are rare and occur in only 2% of patients. However, both lethal and non-lethal events follow the same pattern.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388934

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  9 in total

1.  Structural models for the KCNQ1 voltage-gated potassium channel.

Authors:  Jarrod A Smith; Carlos G Vanoye; Alfred L George; Jens Meiler; Charles R Sanders
Journal:  Biochemistry       Date:  2007-11-14       Impact factor: 3.162

2.  Protein kinase C downregulates I(Ks) by stimulating KCNQ1-KCNE1 potassium channel endocytosis.

Authors:  Vikram A Kanda; Kerry Purtell; Geoffrey W Abbott
Journal:  Heart Rhythm       Date:  2011-05-10       Impact factor: 6.343

3.  Pharmacological dissection of K(v)7.1 channels in systemic and pulmonary arteries.

Authors:  Preet S Chadha; Friederike Zunke; Alison J Davis; Thomas A Jepps; Joannes T M Linders; Michael Schwake; Rob Towart; Iain A Greenwood
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.

Authors:  Margrith E Mattmann; Haibo Yu; Zhihong Lin; Kaiping Xu; Xiaofang Huang; Shunyou Long; Meng Wu; Owen B McManus; Darren W Engers; Uyen M Le; Min Li; Craig W Lindsley; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2012-08-02       Impact factor: 2.823

5.  Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity.

Authors:  S Y M Yeung; V Pucovský; J D Moffatt; L Saldanha; M Schwake; S Ohya; I A Greenwood
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

Review 6.  AKAP-scaffolding proteins and regulation of cardiac physiology.

Authors:  J R H Mauban; M O'Donnell; S Warrier; S Manni; M Bond
Journal:  Physiology (Bethesda)       Date:  2009-04

7.  Detection of a new KCNQ1 frameshift mutation associated with Jervell and Lange-Nielsen syndrome in 2 Iranian families.

Authors:  Azam Amirian; Zahra Zafari; Mohammad Dalili; Siamak Saber; Morteza Karimipoor; Samira Dabbagh Bagheri; Amir Farjam Fazelifar; Sirous Zeinali
Journal:  J Arrhythm       Date:  2018-04-16

8.  Editorial: Kv7 Channels: Structure, Physiology, and Pharmacology.

Authors:  Thomas A Jepps; Vincenzo Barrese; Francesco Miceli
Journal:  Front Physiol       Date:  2021-04-16       Impact factor: 4.566

9.  Hexachlorophene is a potent KCNQ1/KCNE1 potassium channel activator which rescues LQTs mutants.

Authors:  Yueming Zheng; Xuejing Zhu; Pingzheng Zhou; Xi Lan; Haiyan Xu; Min Li; Zhaobing Gao
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.